Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.
The Journal of dermatological treatment
View this publicationThe Journal of dermatological treatment
View this publicationThe Journal of dermatological treatment
View this publicationPublication categories: Top publication
Nature communications
View this publicationCell death discovery
View this publicationJournal of immunology (Baltimore, Md. : 1950)
View this publicationPsychopharmacology
View this publicationInfection
View this publicationJournal of immunology (Baltimore, Md. : 1950)
View this publicationeLife
View this publicationbioRxiv : the preprint server for biology
View this publication